Authors
Gately, KathyCollins, Ian
Forde, Lydia
Al-Alao, Bassel
Young, Vincent
Gerg, Michael
Feuerhake, Friedrich
O'Byrne, Kenneth
Affiliation
Department of Clinical Medicine, Trinity College Dublin, St. James Hospital,, Dublin 8, Ireland. kgately@stjames.ieIssue Date
2012-02-01T10:44:49ZMeSH
AgedBlotting, Western
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Lung Neoplasms/*metabolism/mortality/pathology
Male
Middle Aged
Prognosis
Receptor, IGF Type 1/*biosynthesis
Small Cell Lung Carcinoma/*metabolism/mortality/pathology
Tumor Markers, Biological/*analysis
Metadata
Show full item recordCitation
Clin Lung Cancer. 2011 Jan;12(1):38-42.Journal
Clinical lung cancerDOI
10.3816/CLC.2011.n.005PubMed ID
21273178Abstract
BACKGROUND: Small-cell lung cancer (SCLC) is an aggressive disease with a poor prognosis. The insulin-like growth factor-1 receptor (IGF-1R) is an autocrine growth factor and an attractive therapeutic target in many solid tumors, but particularly in lung cancer. PATIENTS AND METHODS: This study examined tumor samples from 23 patients diagnosed with SCLC, 11 resected specimens and 12 nodal biopsies obtained by mediastinoscopy, for expression of IGF-1R using the monoclonal rabbit anti-IGF-1R (clone G11, Ventana Medical Systems, Tucson, AZ) and standard immunohistochemistry (IHC). RESULTS: All 23 tumor samples expressed IGF-1R with a range of stain intensity from weak (1+) to strong (3+). Ten tumors had a score of 3+, 7 tumors 2+, and 6 tumors 1+. Patient survival data were available for all 23 patients. Two patients died < 30 days post biopsy, therefore, the intensity of anti-IGF-1R immunostaining for 21 patients was correlated to survival. Patients with 3+ immunostaining had a poorer prognosis (P = .003). The overall survival of patients who underwent surgical resection was significantly better (median survival not reached) than patients who were not resected (median survival, 7.4 months) (P = .006). CONCLUSION: IGF-1R targeted therapies may have a role in the treatment of SCLC in combination with chemotherapy or as maintenance therapy. Further studies on the clinical benefit of targeting IGF-1R in SCLC are needed.Language
engISSN
1938-0690 (Electronic)1525-7304 (Linking)
ae974a485f413a2113503eed53cd6c53
10.3816/CLC.2011.n.005